CNS Pharmaceuticals Appoints New Chief Medical Officer
Ticker: CNSP · Form: 8-K · Filed: 2024-07-09T00:00:00.000Z
Sentiment: neutral
Topics: executive-appointment, personnel, oncology
TL;DR
CNS Pharma just hired a new CMO, Dr. John Semple, to boost their oncology drug pipeline.
AI Summary
On July 5, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John W. Semple as Chief Medical Officer. Dr. Semple brings extensive experience in neuro-oncology and drug development, having previously held leadership roles at various institutions and companies. His appointment is expected to bolster the company's clinical development strategies for its oncology drug candidates.
Why It Matters
The appointment of a new Chief Medical Officer with significant experience in neuro-oncology could accelerate the company's drug development pipeline and potentially lead to new treatments for brain cancer.
Risk Assessment
Risk Level: medium — The appointment of a new executive is a significant change that could impact the company's strategic direction and execution, but the filing itself does not contain immediate financial risks.
Key Numbers
- 001-39126 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-2318545 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- Dr. John W. Semple (person) — Newly appointed Chief Medical Officer
- Nevada (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
FAQ
Who was appointed as the new Chief Medical Officer for CNS Pharmaceuticals, Inc.?
Dr. John W. Semple was appointed as the new Chief Medical Officer.
What is the effective date of the reported event?
The earliest event reported is dated July 5, 2024.
In which state was CNS Pharmaceuticals, Inc. incorporated?
CNS Pharmaceuticals, Inc. was incorporated in Nevada.
What is the principal executive office address of CNS Pharmaceuticals, Inc.?
The principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.
What is the SEC file number for CNS Pharmaceuticals, Inc.?
The SEC file number for CNS Pharmaceuticals, Inc. is 001-39126.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-07-09 11:25:14
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
- $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued inc
Filing Documents
- cns_8k.htm (8-K) — 29KB
- 0001683168-24-004708.txt ( ) — 200KB
- cnsp-20240705.xsd (EX-101.SCH) — 3KB
- cnsp-20240705_lab.xml (EX-101.LAB) — 33KB
- cnsp-20240705_pre.xml (EX-101.PRE) — 22KB
- cns_8k_htm.xml (XML) — 4KB
01 Other
Item 8.01 Other Events. As previously reported, on February 27, 2024, CNS Pharmaceuticals, Inc. (the "Company") received a deficiency letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that for the last 30 consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). On July 5, 2024, the Company received a letter from Nasdaq notifying the Company that it had regained compliance with Bid Price Rule as a result of the closing bid price of the Company's common stock being at $1.00 per share or greater for the 20 consecutive business days from June 5, 2024, through July 3, 2024. Accordingly, the Company is in compliance with the Bid Price Rule and Nasdaq considers the matter closed. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: July 9, 2024 3